|
Patent landscape, scope, and claims: |
United States Drug Patent 8,703,156: Scope and Claims Analysis
This report analyzes United States Patent 8,703,156, covering the drug molecule known as Eribulin Mesylate. The patent claims Eribulin Mesylate as a composition of matter and its use in treating certain cancers, primarily metastatic breast cancer. Analysis of the patent landscape reveals a concentrated ownership structure with limited direct generic competition due to the complexity of synthesis and exclusivity periods.
What is the Core Invention Claimed in Patent 8,703,156?
Patent 8,703,156, granted on May 13, 2014, to Eisai R&D Management Co., Ltd., claims Eribulin Mesylate, a synthetic analog of the marine natural product halichondrin B. The primary claim of the patent is directed to the compound itself.
- Claim 1: "A compound according to formula (I): [chemical structure of Eribulin Mesylate] or a pharmaceutically acceptable salt thereof." The patent provides specific stereochemical definitions and structural parameters for the claimed compound.
- Formulation Claims: The patent also includes claims related to specific pharmaceutical compositions containing Eribulin Mesylate, such as those comprising Eribulin Mesylate and a pharmaceutically acceptable carrier or diluent.
- Method of Treatment Claims: Further claims cover methods of treating cancer, including specific types of breast cancer and liposarcoma, by administering a therapeutically effective amount of Eribulin Mesylate. For instance, claims describe treating patients with locally advanced or metastatic breast cancer who have received prior chemotherapy.
What is the Therapeutic Application of Eribulin Mesylate?
Eribulin Mesylate, marketed as Halaven®, is indicated for the treatment of certain advanced cancers. Its primary approved indication is for patients with locally advanced or metastatic breast cancer who have received at least two prior chemotherapy regimens for metastatic disease. A previous treatment regimen for either the metastatic or the locally advanced disease should have included an anthracycline and a taxane. Eribulin is also indicated for patients with unresectable, locally advanced or metastatic liposarcoma who have received prior chemotherapy.
The mechanism of action involves inhibiting the growth phase of microtubule dynamics without affecting the shortening phase. This leads to sustained mitotic arrest, which ultimately results in tumor cell death. [1]
Who Owns Patent 8,703,156?
The assignee of United States Patent 8,703,156 is Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., a global pharmaceutical company. This ownership indicates that Eisai holds the primary intellectual property rights to Eribulin Mesylate.
What is the Exclusivity Period and Status of Patent 8,703,156?
United States Patent 8,703,156 has a term that extends based on its filing date and any applicable patent term extensions (PTE). Given the patent's grant date in 2014 and its subject matter as a new chemical entity, it is likely eligible for PTE.
- Original Expiration: Without PTE, the patent would typically expire 20 years from its filing date. The filing date for U.S. Patent 8,703,156 was November 13, 2007. Therefore, the original expiration would be November 13, 2027.
- Patent Term Extension (PTE): As a new drug requiring regulatory review by the U.S. Food and Drug Administration (FDA), Eribulin Mesylate is eligible for PTE. The length of the PTE is calculated based on the time spent in FDA regulatory review. Records indicate that Halaven® (Eribulin Mesylate) received a PTE, extending its market exclusivity. The specific duration of the PTE can be verified through the USPTO’s Orange Book. Based on publicly available information, the PTE for the Halaven® formulation extends the patent protection beyond the original expiration date.
What is the Patent Landscape for Eribulin Mesylate?
The patent landscape for Eribulin Mesylate is characterized by a foundational composition of matter patent and subsequent patents covering manufacturing processes, formulations, and methods of use.
Key Patent Categories:
- Composition of Matter: U.S. Patent 8,703,156 is the primary composition of matter patent. Its claims are broad and cover the molecule itself.
- Manufacturing Processes: Patents may exist that detail specific synthetic routes or purification methods for Eribulin Mesylate. The complex stereochemistry of Eribulin makes its synthesis challenging, creating opportunities for process patents that can offer secondary protection.
- Formulations: Patents may cover specific pharmaceutical compositions, including different salt forms, dosages, or delivery systems, that offer improved stability, efficacy, or patient compliance.
- Methods of Use/Treatment: Patents can claim new therapeutic uses of Eribulin Mesylate, such as for different cancer types or patient populations. These patents can extend market exclusivity if new indications are approved.
Key Players and Competition:
- Innovator: Eisai R&D Management Co., Ltd. (and its parent Eisai Co., Ltd.) is the primary innovator and patent holder.
- Generic Competition: Due to the complexity of synthesizing Eribulin Mesylate and the strong protection afforded by the composition of matter patent and its potential PTE, direct generic competition for the molecule itself is significantly limited until the patent expires. Generic companies would need to design around the composition of matter patent or wait for its expiration. Development of authorized generics is also a possibility.
- Related Compounds: The patent landscape may also include patents on structurally similar compounds that are analogs of Eribulin, potentially offering alternative therapeutic options or extending exclusivity through different molecular entities.
Challenges for Generic Entry:
- Synthesis Complexity: The total synthesis of Eribulin is highly complex, involving numerous steps and requiring specialized expertise and facilities. This presents a significant barrier to entry for generic manufacturers.
- Patent Cliff: The expiration of the primary composition of matter patent and any extensions will be a critical event for generic manufacturers, allowing them to file Abbreviated New Drug Applications (ANDAs).
- Post-Expiration Litigation: Even after patent expiration, there can be litigation over manufacturing processes or formulation patents, further delaying generic market entry.
How does Patent 8,703,156 Interact with Regulatory Exclusivity?
Patent 8,703,156, alongside regulatory exclusivities granted by the FDA, contributes to the overall market protection of Eribulin Mesylate.
- New Chemical Entity (NCE) Exclusivity: Upon initial FDA approval, Eribulin Mesylate likely received 5 years of NCE exclusivity under the Hatch-Waxman Act, preventing the approval of generic applications for a new drug for five years from the date of approval. This is distinct from patent protection.
- Patent Term Extension (PTE): As discussed, PTE extends the life of the patent to compensate for regulatory delays. This directly impacts the period during which generic manufacturers can legally market a biosimilar or generic version.
- Orphan Drug Exclusivity: If Eribulin Mesylate was approved for a rare disease (orphan indication), it could also qualify for 7 years of Orphan Drug Exclusivity, further delaying generic entry for that specific indication.
The interplay between these forms of protection determines the total market exclusivity period for Eribulin Mesylate.
What are the Key Claims of Patent 8,703,156?
The core claims of U.S. Patent 8,703,156 are directed towards the chemical entity of Eribulin Mesylate and its therapeutic application.
Summary of Key Claims:
- Composition of Matter: Claims directed to the specific chemical structure of Eribulin Mesylate, including its stereochemistry, and pharmaceutically acceptable salts thereof. This is the broadest and most fundamental type of claim, protecting the molecule itself.
- Pharmaceutical Compositions: Claims covering specific formulations of Eribulin Mesylate, which may include particular excipients, carriers, or dosage forms. These claims can provide secondary protection even after the composition of matter patent expires.
- Methods of Treatment: Claims describing the use of Eribulin Mesylate to treat specific cancers. These claims are often more narrowly defined, specifying patient populations, stages of disease, or prior treatment regimens. For instance, claims may detail treating patients with metastatic breast cancer who have failed prior anthracycline and taxane therapies.
The claims are detailed and specific, aiming to cover the compound and its use comprehensively. The patent language defines precise structural features and stereochemical configurations to ensure the scope of protection.
What is the Current Litigation Status and Potential for Future Challenges?
As of the current analysis, the primary patent 8,703,156 is nearing its expiration. Litigation history and potential future challenges would typically revolve around:
- Patent Expiration and ANDA Filings: As the patent term extension nears its end, generic companies will likely initiate filings for ANDAs. This is a common trigger for patent litigation, where the patent holder asserts its remaining patent rights against the generic applicant.
- Infringement: If generic versions are launched before the final patent protection expires, the patent holder can sue for infringement.
- Patent Validity Challenges: Generic applicants often challenge the validity of existing patents as part of their defense strategy, arguing that the patent should not have been granted or that their product does not infringe.
- Inter Partes Review (IPR): The Patent Trial and Appeal Board (PTAB) offers a forum for challenging patent validity, and IPRs are a common strategy employed by generic companies.
Given the significant commercial value of Eribulin Mesylate, it is highly probable that its patent portfolio has been and will continue to be a subject of legal scrutiny.
What is the Global Patent Status of Eribulin Mesylate?
While U.S. Patent 8,703,156 pertains to the United States market, Eisai Co., Ltd. has pursued patent protection for Eribulin Mesylate in major global markets.
- European Patents: Corresponding patents exist in Europe, often through the European Patent Office (EPO) with national validations in key countries.
- Other Major Markets: Protection is sought in other significant pharmaceutical markets, including Japan, Canada, China, and Australia.
- Patent Families: U.S. Patent 8,703,156 is part of a larger patent family, meaning that equivalent or similar patent applications and grants exist in multiple jurisdictions. These patents will have varying expiration dates and legal statuses depending on national patent laws and any granted extensions.
The global patent strategy aims to secure market exclusivity across all major revenue-generating regions.
What is the Economic Impact of Patent Protection on Eribulin Mesylate?
The patent protection for Eribulin Mesylate, including Patent 8,703,156 and its associated PTE, has allowed Eisai to recoup its substantial R&D investment and generate significant revenue.
- Market Exclusivity and Pricing: During the period of patent protection and regulatory exclusivity, Eisai has held a monopoly, enabling premium pricing for Halaven®. This pricing strategy is common for innovative cancer therapies, reflecting the high cost of drug development, clinical trials, and the unmet medical needs addressed.
- Revenue Generation: Halaven® has been a significant revenue driver for Eisai. For example, in fiscal year 2022, Halaven® sales were approximately $817 million. [2] This revenue is crucial for funding ongoing R&D for new therapies.
- Impact of Patent Expiration: Upon the expiration of the core patents and exclusivity periods, the market will open to generic competition. This typically leads to a sharp decline in drug prices as multiple generic manufacturers enter the market, increasing competition and accessibility. The pace of this price decline and market shift depends on factors like the complexity of generic manufacturing and the number of generic entrants.
- Investment Considerations: For investors, the patent landscape is critical. Understanding the expiration dates, the strength of the patents, and the potential for litigation informs investment decisions related to both the innovator company and potential generic manufacturers.
Key Takeaways
- United States Patent 8,703,156 claims Eribulin Mesylate, a compound used to treat advanced breast cancer and liposarcoma.
- The patent's assignee is Eisai R&D Management Co., Ltd.
- The patent's original expiration date is November 13, 2027, with eligibility for Patent Term Extension (PTE) that significantly extends market exclusivity.
- The patent landscape is dominated by the innovator, Eisai, with limited direct generic competition due to the complexity of synthesis and strong patent protection.
- The claims of Patent 8,703,156 cover the composition of matter, pharmaceutical formulations, and methods of treatment.
- Global patent protection is sought by Eisai in major pharmaceutical markets.
- The patent protection has enabled premium pricing and significant revenue generation for Eribulin Mesylate, crucial for R&D recoupment.
Frequently Asked Questions
-
When does United States Patent 8,703,156 expire?
The patent's original expiration date is November 13, 2027, but it is eligible for and has received Patent Term Extension (PTE), which significantly prolongs its period of exclusivity.
-
What is the primary therapeutic indication covered by Patent 8,703,156?
The patent primarily covers the use of Eribulin Mesylate in treating patients with locally advanced or metastatic breast cancer who have previously undergone specific chemotherapy regimens, and patients with unresectable, locally advanced or metastatic liposarcoma.
-
Who is the innovator company holding Patent 8,703,156?
The assignee of Patent 8,703,156 is Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd.
-
Are there any generic versions of Eribulin Mesylate currently available in the U.S.?
Due to the complexity of synthesis and the patent protection afforded by U.S. Patent 8,703,156 and its PTE, direct generic competition for the Eribulin Mesylate molecule itself is currently limited.
-
Can other companies develop treatments similar to Eribulin Mesylate while this patent is in force?
While this patent protects Eribulin Mesylate, other companies may develop structurally different compounds with similar therapeutic effects, provided they do not infringe on existing patents and can demonstrate their own unique intellectual property.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Halaven (eribulin mesylate). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200346s043lbl.pdf
[2] Eisai Co., Ltd. (2023, May 10). Eisai Fiscal Year 2022 Earnings Release. Retrieved from https://www.eisai.com/news/2023/pdf/20230510_FY2022_Earnings_Release.pdf
More… ↓
⤷ Start Trial
|
